Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 101 to 110 of 471 total matches.
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
of all ages due to prolonged wearing of masks during
the COVID-19 pandemic.1 Guidelines for treatment ...
Acne is common among adolescents and young adults,
but its prevalence appears to have increased in people
of all ages due to prolonged wearing of masks during
the COVID-19 pandemic. Guidelines for treatment of
acne were last published in 2016.
Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
in patients with
severe active ulcerative colitis.
Table 1. Sutab Clinical Trial Results
Trial Regimen1 ...
The FDA has approved an oral tablet formulation of
sodium sulfate, magnesium sulfate, and potassium
chloride (Sutab – Braintree) for colon cleansing prior
to colonoscopy in adults. A sodium sulfate-based oral
solution (Suprep) has been available in the US since
2010. Sutab is the second tablet formulation to be
approved for bowel cleansing prior to colonoscopy;
a sodium phosphate-based tablet (OsmoPrep) was
approved earlier.
In Brief: Semglee - Insulin Glargine Interchangeable with Lantus
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021 (Issue 1634)
will be the same if the patient switches
between the reference product and the biosimilar.1
In an open-label ...
Insulin glargine-yfgn (Semglee – Viatris), a follow-on
insulin glargine product, has now received
interchangeability status with the reference product
Lantus from the FDA. It is the first biosimilar insulin
product to receive this designation in the US. Now a
pharmacist can substitute Semglee for Lantus as a
lower-cost alternative without permission from the
prescriber.
Eptinezumab (Vyepti) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
once monthly (fremanezumab
can also be given once every 3 months), were
approved earlier.1 ...
The FDA has approved eptinezumab-jjmr (Vyepti –
Lundbeck), a calcitonin gene-related peptide (CGRP)
antagonist administered IV once every 3 months, for
migraine prevention in adults. It is the fourth monoclonal
antibody to be approved for this indication; erenumab
(Aimovig), fremanezumab (Ajovy), and galcanezumab
(Emgality), which are all given subcutaneously once
monthly (fremanezumab can also be given once every 3
months), were approved earlier.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • Oct 08, 2018 (Issue 1557)
methods generally have higher failure
rates than other methods.1-3
COMBINATION ORAL CONTRACEPTIVES ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also highly effective
in preventing pregnancy. When used alone, barrier and
fertility-based methods generally have higher failure
rates than other methods.
Jatenzo - An Oral Testosterone for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
.
TESTOSTERONE REPLACEMENT — Oral testosterone
replacement therapy has generally been ineffective
Table 1. Some ...
An oral formulation of testosterone undecanoate
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated
with a deficiency of endogenous testosterone, such as
Klinefelter syndrome, orchiectomy, toxic damage from
chemotherapy or alcohol, or pituitary-hypothalamic
injury from tumors, trauma, or radiation. Jatenzo is
not approved for treatment of low testosterone levels
solely due to aging. It is the first oral testosterone
formulation to be approved in the US.
In Brief: Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
mg per spray
(Narcan) was approved in 2015.1
Pronunciation Key
Kloxxado: kloks ah’ doh
Table 1 ...
The FDA has approved a higher-dose intranasal
naloxone formulation (Kloxxado – Hikma) for
emergency treatment of opioid overdose. A single
spray of the new formulation delivers 8 mg of
naloxone; a formulation that delivers 4 mg per spray
(Narcan) was approved in 2015.
In Brief: An Asenapine Patch (Secuado) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
1). Asenapine was also superior to placebo in
the Clinical Global Impressions-Severity (CGI ...
A transdermal formulation of the second-generation
(atypical) antipsychotic asenapine (Secuado – Noven)
has been approved by the FDA for once-daily treatment of
schizophrenia in adults. Asenapine is the first antipsychotic
to become available in a transdermal formulation in the US.
A twice-daily sublingual tablet formulation of asenapine
(Saphris) has been available since 2009.
Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
hematopoietic cell transplant
(HCT), which can be curative.1
MECHANISM OF ACTION — The antibody-drug ...
The FDA has approved inotuzumab ozogamicin
(Besponsa – Pfizer), a humanized anti-CD22
monoclonal antibody conjugated to the cytotoxic
antibiotic calicheamicin, for treatment of relapsed
or refractory B-cell precursor acute lymphoblastic
leukemia (ALL) in adults. It is the first CD22-directed
antibody-drug conjugate to be approved in the US.
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018 (Issue 1553)
Ciprofloxacin Otic Suspension
Otiprio) for Acute Otitis Externa
Table 1. Some Otic ...
The FDA has approved a 6% otic suspension
formulation of the fluoroquinolone antibiotic
ciprofloxacin (Otiprio – Otonomy) for single-dose
treatment of acute otitis externa (swimmer's
ear) caused by Pseudomonas aeruginosa or
Staphylococcus aureus in patients ≥6 months old.
Otiprio was approved earlier for prophylaxis in
children with bilateral otitis media with effusion who
are undergoing tympanostomy tube placement.